(Reuters) – Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment.
(Reporting by Nate Raymond in Boston; Editing by Aditya Soni)
